These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15714296)

  • 1. Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.
    Avram S; Bologa C; Flonta ML
    J Mol Model; 2005 Mar; 11(2):105-15. PubMed ID: 15714296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between the predicted and the observed biological activity of the symmetric and nonsymmetric cyclic urea derivatives used as HIV-1 protease inhibitors. A 3D-QSAR-CoMFA method for new antiviral drug design.
    Avram S; Svab I; Bologa C; Flonta ML
    J Cell Mol Med; 2003; 7(3):287-96. PubMed ID: 14594553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative molecular field analysis (CoMFA) of a series of symmetrical bis-benzamide cyclic urea derivatives as HIV-1 protease inhibitors.
    Debnath AK
    J Chem Inf Comput Sci; 1998; 38(4):761-7. PubMed ID: 9691478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: application of comparative molecular field analysis.
    Debnath AK
    J Med Chem; 1999 Jan; 42(2):249-59. PubMed ID: 9925730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
    Frecer V; Burello E; Miertus S
    Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
    Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
    Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative structure-activity relationship studies on cyclic cyanoguanidines acting as HIV-1 protease inhibitors.
    Gupta SP; Babu MS
    Bioorg Med Chem; 1999 Nov; 7(11):2549-53. PubMed ID: 10632065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
    Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
    Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A simple clustering technique to improve QSAR model selection and predictivity: application to a receptor independent 4D-QSAR analysis of cyclic urea derived inhibitors of HIV-1 protease.
    Senese CL; Hopfinger AJ
    J Chem Inf Comput Sci; 2003; 43(6):2180-93. PubMed ID: 14632470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible allosteric interactions of monoindazole-substituted P2 cyclic urea analogues with wild-type and mutant HIV-1 protease.
    Garg R; Bhhatarai B
    J Comput Aided Mol Des; 2008 Oct; 22(10):737-45. PubMed ID: 18368496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
    Ala PJ; Huston EE; Klabe RM; McCabe DD; Duke JL; Rizzo CJ; Korant BD; DeLoskey RJ; Lam PY; Hodge CN; Chang CH
    Biochemistry; 1997 Feb; 36(7):1573-80. PubMed ID: 9048541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.
    Hodge CN; Aldrich PE; Bacheler LT; Chang CH; Eyermann CJ; Garber S; Grubb M; Jackson DA; Jadhav PK; Korant B; Lam PY; Maurin MB; Meek JL; Otto MJ; Rayner MM; Reid C; Sharpe TR; Shum L; Winslow DL; Erickson-Viitanen S
    Chem Biol; 1996 Apr; 3(4):301-14. PubMed ID: 8807858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
    Garg R; Bhhatarai B
    Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
    De Lucca GV; Kim UT; Liang J; Cordova B; Klabe RM; Garber S; Bacheler LT; Lam GN; Wright MR; Logue KA; Erickson-Viitanen S; Ko SS; Trainor GL
    J Med Chem; 1998 Jun; 41(13):2411-23. PubMed ID: 9632373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.
    Ala PJ; Huston EE; Klabe RM; Jadhav PK; Lam PY; Chang CH
    Biochemistry; 1998 Oct; 37(43):15042-9. PubMed ID: 9790666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
    Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
    J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative structure-activity relationship studies on cyclic urea-based HIV protease inhibitors.
    Gupta SP; Babu MS; Garg R; Sowmya S
    J Enzyme Inhib; 1998 Sep; 13(6):399-407. PubMed ID: 9825304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple receptor conformation docking and dock pose clustering as tool for CoMFA and CoMSIA analysis - a case study on HIV-1 protease inhibitors.
    Sivan SK; Manga V
    J Mol Model; 2012 Feb; 18(2):569-82. PubMed ID: 21547550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.